Kyle Stuart, Aggeli Amalia, Ingham Eileen, McPherson Michael J
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK.
Trends Biotechnol. 2009 Jul;27(7):423-33. doi: 10.1016/j.tibtech.2009.04.002. Epub 2009 Jun 6.
Self-assembling peptide-based biomaterials are being developed for use as 3D tissue engineering scaffolds and for therapeutic drug-release applications. Chemical synthesis provides custom-made peptides in small quantities, but production approaches based upon transgenic organisms might be more cost-effective for large-scale peptide production. Long lead times for developing appropriate animal clones or plant lines and potential negative public opinion are obstacles to these routes. Microbes, particularly safe organisms used in the food industry, offer a more rapid route to the large-scale production of recombinant self-assembling biomaterials. In this review, recent advances and challenges in the recombinant production of collagen, elastin and de novo designed self-assembling peptides are discussed.
基于自组装肽的生物材料正在被开发用于三维组织工程支架和治疗性药物释放应用。化学合成可少量提供定制肽,但基于转基因生物的生产方法对于大规模肽生产可能更具成本效益。开发合适的动物克隆或植物品系所需的较长准备时间以及潜在的负面公众舆论是这些途径的障碍。微生物,特别是食品工业中使用的安全生物体,为重组自组装生物材料的大规模生产提供了一条更快的途径。在这篇综述中,讨论了胶原蛋白、弹性蛋白和从头设计的自组装肽的重组生产的最新进展和挑战。